Type 2 Diabetes (T2D) Female Case with Clinical Efficacy of Vildaglipin, Metformin and Imeglimin

Hatakeyama S, Bando H, Iwatsuki N, Okada M, Ogawa T and Sakamoto K

Published on: 2024-05-06

Abstract

The current case is a 63-year-old female patient with Type 2 Diabetes (T2D) who was treated for oral hypoglycemic agents (OHAs). During 2019–2020, she was diagnosed with Bowen’s disease with skin problems in the inguinal region and a urinary tract infection (UTI). Then she discontinued SGLT-2i. In April 2022, HbA1c was increased to 8.1%, and then vildagliptin/metformin (EquMet) was begun with clinical effect. After HbA1c exacerbation in September 2022, imeglimin (Twymeeg) was added with a satisfactory effect of a 1.4% decrease for 10 months. Clinical progress will be followed up for related OHAs and other various factors with close attention.